Corel office document
IN THE SUPREME COURT OF NOVA SCOTIA
Cherny v. Glaxo Smith Kline Inc., 2008 NSSC 345
S. H. No. 201450
November 13, 2008, in Halifax, Nova Scotia
Kevin P. Downie, Gavin Giles,Q.C. and Wylie Spicer, Q.C. Solicitors for the Plaintiff
Teresa J. Walsh and Gordon F. Proudfoot, Q.C. Solicitors for the Defendant
By the Court
The Defendant brings this Application under Rule 13.01
of the Civil
seeking an Order of Summary Judgment.
The Plaintiff, Vladimir Cherny, obtained a prescription from his family
doctor for a drug marketed by the Defendant, under the name Zyban. The
Defendant markets the drug as an aid to “quit” smoking. It was Mr. Cherny’s
desire to terminate his smoking habit and he had seen advertisements indicating
that this drug would assist him toward that end. He approached his family doctor
with that in mind and as a result obtained a prescription and used the drug for a
period of three weeks. The position of his counsel, on this application, is that at
the end of the three weeks he rapidly lost all the hair on his body. This is a
condition known as alopecia universalis
. The Plaintiff claims that this was an
undisclosed side effect of taking the drug. The loss of hair is the main thrust of
this lawsuit. It should be added, however, that Mr. Cherny claims to have suffered
other side effects including depression and exaggerated libido. I understand the
drug trials undertaken in connection with Zyban disclosed a certain incidence of
depression and/or irritability and increased libido, but; at least as of the time when
Cherny was prescribed the drug; hair loss (alopecia)
had not been reported as a
possible side effect. In subsequent publications, it did appear in the monograph
As I understand trials are conducted with respect to the effects of
consumption of various medications and the positive and adverse effects are noted
and as a result of consistent results using a broad enough sampling, the curative
effects as well as the adverse effects are noted and categorized. After a drug is
marketed, adverse or other effects are noted and when reported are the subject of
revisions in the monograph published for that drug so that the medical community
may become aware. Cherny was prescribed this medication in late 1999. The
following year, “alopecia”
showed up as one of the possible adverse effects in the
monograph published for the drug. The active agent is “bupropion”. Bupropion is
also the active ingredient in Wellbutrin, manufactured by the Defendant and
Wellbutrin likewise has been connected with some incidence of hair loss.
The connection between the consumption of the drug and hair loss or
is anecdotal. No scientific clinical trials have established a connection.
In this circumstance at the intended trial, there will be no opinion offered from a
qualified expert to establish that the consumption of Zyban is the cause of
Cherny’s hair loss. The evidence will be his own and that of other lay persons who
may have some knowledge of his circumstances and it will be anecdotal.
It is the position of the Applicant that the lack of expert evidence
demonstrating the causal connection between the ingestion of the drug and the
consequence of alopecia
is fatal to the case of the Plaintiff as a matter of law.
I am told that the weight of medical evidence is alopecia
is an auto immune
disorder which Mr. Cherny suffered in some degree previous to taking the
medication, that the only connection between his condition and the consumption of
the drug is temporal, and that this is insufficient to establish the causal link in the
This proposition I am not able to accept.
What is the Law?
The relevant provision of our Civil Procedure Rule 13.01
provides that after
the close of pleadings any party may apply to the Court for judgment on the ground
There is no arguable issue to be tried with respect to the claim or any
The test for such an application I understand to have been properly stated in
Selig v. Cook’s Oil Company Ltd.,
2005 NSCA 36, 137 A.C.W.S. (3d) 561. There
are two distinct parts of the test and they should be dealt with sequentially:
 . First the applicant, must show that there is no genuine issue of fact to bedetermined at trial. If the applicant passes that hurdle, then the respondent mustestablish, on the facts that are not in dispute, that his claim has a real chance ofsuccess.
 If the applicant does not establish that there is no genuine issue of fact, it isnot necessary to go to the second step. There is no onus on the responding partyif the applicant does not succeed on the first prong of the test. If there are genuineissues of fact, the application should be dismissed.
It is fair to say that the cases dealing with this provision agree that if the
anticipated evidence will require a determination as to credibility, then it is not an
appropriate case for summary judgment. Put another way, if the facts alleged when
proven, will underpin a cause of action, then the Plaintiff would be entitled to his
trial. In the recent case of Bowden v. Withrow’s Pharmacy Halifax (1999) Ltd.,
 N.S.J. 360, Beveridge, J. reviewed these provisions and quoted from
Williston and Rolls,
at paragraph 11 of that decision:
In every jury case, the legal question to be determined is whether any facts havebeen established by the plaintiff from which liability, if is an issue, may beinferred, but it still remains for the jury to say whether, from those facts, liabilityought to be inferred. If that standard has been met, the case must go to the jury. In ruling on the defendant’s motion, the judge is deciding a question of law andhis decision is therefore subject to review on appeal.
At paragraph 12 Beveridge, J. goes on to quote from Sopinka, Lederman and
Bryant, The Law of Evidence in Canada
An important part of the division of responsibilities between judge and jury is theassessment of the sufficiency of the evidence adduced by a party. If a plaintifffails to lead any material evidence, the plaintiff may be faced with a defendant’snon-suit motion at the close of his or her case. If such a motion is launched, it isthe trial judge’s function to determine whether any facts have been established bythe plaintiff from which liability, if it is in issue, may be inferred. In comparison,it is the trier of fact’s duty to say at the end of the case whether liability ought tobe inferred.
It is apparent that my conclusion is that there will be (on the basis of the
submissions which I have heard) sufficient evidence before the jury at the end of
the trial of this matter that the credibility of the Plaintiff and the value of his
evidence as to the cause of his hair loss, will be a matter to be left to the jury.
Nonetheless, that will be a decision that would more properly be made by the trial
judge than by a judge hearing this preliminary application.
A number of cases have been cited by the Applicant/Defendant in support of
the proposition that expert opinion will be necessary to establish the Plaintiff’s
case or the “causal connection”. I will refer to a number of those cases briefly but I
observe that each of them involve medical malpractice issues where the appropriate
“standard of care” is the defining issue. In MacNeil v. Bethune
(2006) N.S.J. No.
62, an action was taken on behalf of a severely disabled child suffering from
cerebral palsy among other things. Problems had arisen during childbirth and it
was claimed that those problems had caused the child’s condition at the time of the
application to strike the pleadings and grant summary judgement. The applications
Unfortunately, the plaintiff’s own expert reports on their face do not support theallegations of negligence, breach of professional duty and standard of care or
causation. Quite the contrary, there is nothing in these reports to suggest anynegligence on the part of the defendant doctors or the defendant hospital.
The plaintiff must be in a position to put forward at least some specificinformation to show that had a certain procedure or course of treatment beenadministered properly or had some other procedure, course of treatment or seriesof tests been followed, that the outcome of the plaintiff’s condition might havebeen different.
After a review of all of the materials that are before me I find there is no arguableissue to be tried with respect to this claim. This claim has virtually no chance ofsuccess. The defendant’s application for summary judgment is granted pursuantto C.P.R. 13.01. The action is dismissed.
For the reasons already stated, it is my view that this case can be
distinguished. There, the child suffered multiple deficits of a complex nature. The
mother had become ill during pregnancy and required hospitalization and treatment
and there was apparently fetal distress. The defendant physicians were to testify to
the effect that they had ordered all tests and performed all investigations that were
appropriate and that the condition of the child at birth was not caused by any
negligence on their part. The plaintiffs were unable to produce any professional
An Ontario decision Maslen v. Chishlom
 O.J. No. 3960 reports an
application under a similar provision of the Rules in Ontario. It is again a medical
malpractice suit in which the applicant quotes paragraph 8 and 9:
When presented at a trial with the opinion of two expert physicians that thedefendant physician’s conduct was not a causal factor in the plaintiff’s jury, andthe defendant physicians met the standard of care required of them by their peers,the judge (no matter how sympathetic he or she no doubt will be) will not acceptthe uninformed opinion of the lay plaintiff, even if bolstered by the plaintiff’sinterpretation of the medical texts.
Indeed, even if the absence of the defence medicals, I doubt that the plaintiff canmeet the burden of proof that all plaintiffs, even those involved in medicalnegligence cases, must meet, without himself adducing expert medical testimony.
Further another Ontario case dealing again with a medical malpractice
action, indeed decided by the same Judge Claus v. Wolfman
 O.J. No. 5023
is quoted by the Applicant at paragraph 12:
In my view, it would therefore be open to a court to grant a summary judgmentdismissing a claim of this nature even without the expert opinion of thedefendants. The court ought not to be asked to make a finding that an expert orexperts (the defendants) failed to meet the standard required of them by theirprofessional peers and that their malpractice was the cause or a significant
causative factor in the plaintiff’s injury, in the absence of evidence of what thestandard is and without the expression of even a guarded professional opinion thatthe defendants’ conduct may have been a causal factor.
A case from British Columbia was cited which involved an action against a
drug company. That is Trueman v. Ripley
 B.C.J. No. 2060. In that case
action was taken against medical doctors for professional malpractice and against
the drug company Upjohn. The action against Upjohn was statute barred because
of limitation. At paragraphs 32, 33 and 34 of the case there is an interesting
discussion about proving the causal link between a drug and an adverse effect and
the quality of the evidence which will be relied upon by the medical and scientific
communities as proof of the causal connection between a particular drug and a
particular result. The procedure in this particular case taken under Rule 18.A
B.C. Supreme Court Rules appears to have been a summary trial, so that evidence
was taken, a circumstance somewhat different than in the present case. The nature
of the discussion in the paragraphs quoted describes the kind of “hill” which Mr.
Cherny must climb in order to prove his case. It is said quoting from paragraph 32
. there are only two methodologies generally accepted by the medical andscientific communities with respect to drawing the conclusion that the ingestionof a drug may cause an adverse medical event:
controlled clinical studies where subjects are given a drug in acontrolled setting and the drug is compared with other drugs orplacebo; and
epidemiological studies, where defined human populations,including those who have already been prescribed the drug, arestudied.
The authority goes on to say that spontaneous reporting of adverse results and/or
instances where doctors have reported observations of adverse effects are only
anecdotal and can only form the hypothesis for clinical testing which testing is then
Counsel on behalf of the Plaintiff has emphasised the need for a Judge to be
“satisfied” that the Plaintiff cannot prove the necessary essential facts before a
summary judgment should be granted against him. To use the colloquial term the
Plaintiff should have his “day in Court”. On his behalf, Mr. Spicer emphasises the
remarkable timing of the ingestion of the drug and the time of the hair loss. He
points out that alopecia
was recognized as a side effect of Wellbutrin by the drug
company before 1999 and that it was acknowledged with respect to Zyban in the
year following Cherny’s hair loss. He emphasises, as well, the fact that Mr.
Cherny had experienced difficulty with alopecia
, a word with which he was
familiar and understood, before he sought this medication to assist in his battle
against nicotine. Counsel argues that if that word had appeared as a possible side
effect of using this drug, then his client would clearly not have used it. On this
application he argues that the expert’s report produced on behalf of the Defendant,
Dr. Cheryl Rosen, a physician and an associate professor at the University of
Toronto is not unequivocal in its conclusions, although finally expressing the view
that there is “no connection” between Zyban and Mr. Cherny’s alopecia
At this stage at least, I think it is appropriate that the finder of fact should
have an opportunity to assess the weight they will be prepared to give to the
evidence offered by Mr. Cherny and his witnesses against the weight which they
will be prepared to give to the expert evidence which will presumably be offered
The Application for summary judgement is denied with costs in the cause.
This document is designed to provide guidance to pharmacists on a range of issues including appropriate and effective processes, desired behaviour of good practice, how professional responsibilities may be best fulfilled, and expected outcomes. At all times, pharmacists must meet any legislative requirements and are expected to exercise professional judgment in adapting the guidance provided here
SELECTED HSRN ANNOTATED BIBLIOGRAPHY, 2003-2011 (Updated April 2011). The IMS Health Services Research Network is comprised of academic researchers who are conducting empirically rigorous, policy-relevant studies to improve the quality and cost-effectiveness of health care in the United States. The network includes members from a variety of complementary disciplines including pharmacy, me